CATT Study Update 4: Avastin vs. Lucentis Study Ready to Roll
In particular: What Is Neovascular AMD and Why Is the CATT Study Important?
This section provides an explanation of what AMD is and how it is treated, along with some information about the CATT Study, its design and aims.
The Study’s primary aim is to evaluate the relative safety and efficacy of treatment of subfoveal AMD with both Avastin and Lucentis, determine an appropriate dosing schedule and, to see if there is any clinical difference between the two drugs. Some of the secondary aims include:
- Determination of the number of treatments required at 1 and 2 year periods
- Determination if either or both drugs provide a 3-line change in visual acuity (15 letters on ETDRS chart)
- Changes in subretinal and intraretinal fluid on OCT examination
- Changes in lesion size on fluorescein angiograph examination
- Incidence of any complications of treatment (endophthalmitis, retinal detachment, cataract, uveitis)
- Incidences of other adverse effects
- Comparison of the cost of treatment over two years
There are two links within the document: one describes the eligibility requirements, while the second is a 258 page Manual of Procedures, which contains everything your ever wanted to know about the CATT Study.
The only changes I noted from the original information I have provided are that enrollment is now scheduled to begin January 1st, and the number of clinical sites has been reduced to 44. The location of the 44 sites is not provided on the website (yet), but hopefully will be included soon.
In any event, I have a prior list of 45 sites which presumably contains all of the sites scheduled to participate. Anyone wishing to know what sites are participating in their states can email me and I will be happy to provide a list for that state. (My email link is shown in the sidebar.)